VersaFoam Logo   Home Site Map Terms of Use Privacy Stiefel Laboratories Contact Us  
The VersaFoam Advantage
Optimizes delivery
Patient preference
Compliance
Suitable for multiple body areas
Easy to apply
Scientific Data
Bibliography
 
References:

2 Gottlieb AB, Odom Ford R, Spellman MC. The Efficacy and Tolerability of Clobetasol Propionate Foam 0.05% in the Treatment of Mild to Moderate Plaque-type Psoriasis of Nonscalp Regions. J Cut Med Surgery: 2003:7:185-192. (see pages 190-192)

3 Data on file, Stiefel Laboratories
 
Compliance.2-3
VERSAFOAM-HF™
Likelihood of Compliance vs Other Vehicles*

*In a post-study questionnaire, most patients expressed the likelihood to comply with VERSAFOAM-HF foam formulation at least 75% of the time for a 14-day regimen.3
VERSAFOAM-EF™
Likelihood of Compliance vs Other Vehicles *†3
graph

*A Patient Poststudy Questionnaire (N = 581) was administered at the Week 4 evaluation during the phase 3 clinical trial to determine patient preferences regarding topical medications.

†Results based on the proportion of patients who would comply at least 75% of the time with the specified formulation twice a day for a month.